<DOC>
	<DOC>NCT02748512</DOC>
	<brief_summary>A controlled, multi-center study to evaluate the utilization and safety of the MK II inserter and the safety of the Fluocinolone Acetonide Intravitreal (FAI) insert in subjects with non-infectious uveitis affecting the posterior segment of the eye.</brief_summary>
	<brief_title>A Controlled, Multi-center Study of the Utilization and Safety of the MK II Inserter and the Safety of the FAI Insert in Subjects With Non-infectious Uveitis Affecting the Posterior Segment of the Eye</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Panuveitis</mesh_term>
	<mesh_term>Uveitis, Posterior</mesh_term>
	<mesh_term>Uveitis, Intermediate</mesh_term>
	<mesh_term>Pars Planitis</mesh_term>
	<criteria>1. Male or nonpregnant female at least 18 years of age at time of consent 2. At least one eye has a history of noninfectious uveitis affecting the posterior segment 3. Subject has ability to understand and sign the Informed Consent Form 4. Subject is willing and able to comply with study requirements 1. Allergy to fluocinolone acetonide or any component of the FAI insert 2. Ocular malignancy in either eye, including choroidal melanoma 3. Uveitis with infectious etiology 4. Current viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella 5. Current mycobacterial infections of the eye or fungal diseases of ocular structures 6. Subjects who yield, during screening, a confirmed positive test for human immune deficiency virus (HIV) or syphilis 7. Systemic infection within 30 days prior to study Day 1 8. Peripheral retinal detachment in area of insertion 9. Elevated intraocular pressure (IOP) &gt; 21 mmHg, or chronic hypotony &lt; 6 mmHg 10. Concurrent therapy at Screening with IOPlowering pharmacologic agent in the study eye 11. Current diagnosis of any form of glaucoma or ocular hypertension in study eye at Screening, unless study eye has been previously treated with an incisional surgery procedure that has resulted in stable IOP in the normal range (1021 mmHg) 12. Known history of clinically significant IOP elevation in response to steroid treatment in either eye, unless study eye has been previously treated with an incisional surgery procedure that has resulted in stable IOP in the normal range (1021 mmHg) 13. Ocular surgery or capsulotomy performed on the study eye within 30 days prior to study Day 1 14. Intravitreal treatment of study eye: with FAI insert within 36 months prior to study Day 1; with Retisert within 30 months prior to study Day 1; with Ozurdex within 90 days prior to study Day 1; or with Triesence or Trivaris within 30 days prior to study Day 1 15. Periocular or subtenon steroid treatment of study eye within 30 days prior to study Day 1 16. Treatment with an investigational drug or device within 30 days prior to study Day 1, except the FAI insert within this protocol 17. Pregnant or nursing females; females of childbearing potential who are unwilling or unable to use an acceptable method of contraception as outlined in this protocol from at least 14 days prior to study Day 1 until the Month 12 Visit 18. Any condition which, in the judgment of the Investigator, could make the subject inappropriate for entry into this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>